Rafferty Asset Management LLC Acquires 10,863 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Rafferty Asset Management LLC grew its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 16.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 78,690 shares of the company’s stock after purchasing an additional 10,863 shares during the period. Rafferty Asset Management LLC’s holdings in Nurix Therapeutics were worth $2,088,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its stake in Nurix Therapeutics by 89.6% during the first quarter. The Manufacturers Life Insurance Company now owns 13,310 shares of the company’s stock worth $414,000 after buying an additional 6,290 shares during the period. Victory Capital Management Inc. grew its position in shares of Nurix Therapeutics by 17.1% during the 1st quarter. Victory Capital Management Inc. now owns 12,680 shares of the company’s stock worth $394,000 after buying an additional 1,851 shares in the last quarter. Rhumbline Advisers increased its position in Nurix Therapeutics by 108.3% during the 1st quarter. Rhumbline Advisers now owns 24,215 shares of the company’s stock valued at $753,000 after purchasing an additional 12,592 shares during the period. Cambridge Investment Research Advisors Inc. bought a new position in Nurix Therapeutics in the first quarter worth approximately $902,000. Finally, American International Group Inc. raised its position in shares of Nurix Therapeutics by 106.0% in the 1st quarter. American International Group Inc. now owns 13,953 shares of the company’s stock worth $434,000 after acquiring an additional 7,181 shares in the last quarter. Institutional investors own 89.29% of the company’s stock.

In other Nurix Therapeutics news, General Counsel Christine Ring sold 3,200 shares of the stock in a transaction dated Tuesday, September 7th. The stock was sold at an average price of $35.25, for a total value of $112,800.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Pierre Beaurang sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 10th. The stock was sold at an average price of $29.86, for a total transaction of $223,950.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,600 shares of company stock valued at $652,878. 6.30% of the stock is currently owned by corporate insiders.

Several research analysts have recently issued reports on NRIX shares. Needham & Company LLC started coverage on Nurix Therapeutics in a research note on Thursday, July 15th. They issued a “buy” rating and a $48.00 price objective for the company. Zacks Investment Research upgraded Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 16th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Nurix Therapeutics presently has an average rating of “Buy” and a consensus price target of $49.20.

NRIX opened at $36.00 on Friday. The stock has a market capitalization of $1.60 billion, a PE ratio of -15.45 and a beta of 2.47. Nurix Therapeutics, Inc. has a one year low of $21.53 and a one year high of $52.38. The business’s 50 day moving average price is $31.27 and its 200 day moving average price is $30.78.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Monday, July 12th. The company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.06). The company had revenue of $7.09 million during the quarter, compared to analyst estimates of $9.24 million. Nurix Therapeutics had a negative net margin of 389.44% and a negative return on equity of 28.14%. As a group, equities analysts predict that Nurix Therapeutics, Inc. will post -2.48 earnings per share for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Read More: What is Considered a Good Return on Equity (ROE)?

Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIX).

Institutional Ownership by Quarter for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.